First-in-human trial shows microimplant enables remote intracranial pressure monitoring in hydrocephalus

This first-in-human safety and initial efficacy trial evaluated a novel, implantable microimplant (0.28 g) designed for long-term intracranial pressure (ICP) monitoring within the cerebral cortex. The study enrolled 20 patients with hydrocephalus (10 adults and 10 children) in a mixed home and hospital setting, with follow-up for up to 18 months. No comparator group was specified, and primary and secondary outcomes were not formally reported.

The main findings indicate the device was capable of remote ICP monitoring in patients at home for the duration of the study. In several children, shunt failures that occurred were associated with raised ICP readings. Physicians were reportedly able to obtain real-time ICP data that could inform management changes. No specific numerical data, effect sizes, or statistical measures were provided for these observations.

Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the very small sample size, the absence of a control group, and the lack of reported statistical analysis. The study represents a preliminary proof-of-concept. While the technology shows potential for remote monitoring in a complex condition, its clinical utility, safety profile, and impact on patient outcomes remain to be established in more rigorous trials.